R54 Targets Epithelial-Mesenchymal Transition in Ovarian Cancer Cells
Author Information
Author(s): Russo Daniela, Spina Anna, Portella Luigi, Bello Anna Maria, Galdiero Francesca, Trotta Anna Maria, Ieranò Caterina, Rea Giuseppina, Cecere Sabrina Chiara, Coppola Elisabetta, Di Maro Salvatore, Pignata Sandro, Califano Daniela, Scala Stefania
Primary Institution: Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy
Hypothesis
The study aims to evaluate the effect of the newly developed CXCR4 antagonist R54 on human ovarian cancer cells' aggressiveness.
Conclusion
R54 inhibits ovarian cancer cell proliferation and migration, reverses epithelial to mesenchymal transition, and enhances sensitivity to chemotherapy.
Supporting Evidence
- R54 inhibited ovarian cancer cells' proliferation and migration induced by CXCL12.
- R54 reversed the CXCL12-induced epithelial to mesenchymal transition in ovarian cancer cells.
- Targeting CXCR4 with R54 improved sensitivity to chemotherapy in ovarian cancer cells.
Takeaway
Researchers found that a new drug called R54 can help stop ovarian cancer cells from spreading and make them more sensitive to treatment.
Methodology
The study involved cell culture, migration assays, qRT-PCR, immunofluorescence, and Western blotting to assess the effects of R54 on ovarian cancer cells.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website